MCF-7 human breast cancer cell line (MCF-7)

MCF-7 is a widely utilized human breast cancer cell line established in 1973 at the Michigan Cancer Foundation from the pleural effusion of a patient with metastatic breast adenocarcinoma [4, 6]. It is a cornerstone of oncology research, serving as the primary model for studying estrogen receptor (ER)-positive breast cancer due to its retention of differentiated mammary epithelial characteristics, including the expression of ER alpha and progesterone receptors (PR) [1, 3, 5]. Classified within the Luminal A molecular subtype, MCF-7 cells are typically HER2-negative and exhibit a strong proliferative response to estrogens, making them essential for evaluating endocrine therapies such as tamoxifen and fulvestrant [6, 12]. Beyond hormone signaling, the cell line is used to investigate diverse biological processes including apoptosis, cell cycle regulation, and the mechanisms of acquired drug resistance [3, 9]. While it is an invaluable tool, researchers must account for its inherent genetic instability and the potential for phenotypic drift across different laboratory strains [6, 12]. Additionally, MCF-7 is frequently employed in the development of novel therapeutic approaches, such as targeted nanoparticle delivery and gene silencing techniques [4].

Other names

Michigan Cancer Foundation-7MCF7MCF 7

Drugs used in MCF-7 models primarily target the estrogen receptor (ER) signaling pathway through competitive inhibition (SERMs), degradation of the receptor (SERDs), or by blocking estrogen synthesis (Aromatase Inhibitors). Other agents include cytotoxic chemotherapies that induce DNA damage or inhibit mitosis.